

**Study Number:** I10482  
**Test Type:** TOX  
**Route:** Dosing in Feed  
**Species/Strain:** Mouse/B6C3F1/N

**I04G: Mean Body Weight Gain**  
**Test Compound:** N-Butylbenzenesulfonamide  
**CAS Number:** 3622-84-2

**Date Report Requested:** 03/10/2023  
**Time Report Requested:** 13:47:56  
**Lab:** Burleson Research Technologies

**Study Number:** I10482  
**Study Gender:** Female  
**PWG Approval Date:** See web page for date of PWG Approval  
**Version:** v1.4.3  
**Stat Version:** v2.9.1A

Study Number: I10482

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Mouse/B6C3F1/N

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 13:47:56

Lab: Burleson Research Technologies

Females: SRBC

Treatment Groups (ppm)

Phase	Days	0		313		625		1250		2500		5000	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	0.7 ± 0.2 *	8	0.9 ± 0.4	8	0.7 ± 0.1	8	0.6 ± 0.1	8	0.7 ± 0.2	8	0.2 ± 0.1	8
	7 - 14	1.1 ± 0.3 *	8	0.6 ± 0.4	8	0.9 ± 0.2	8	0.7 ± 0.3	8	0.6 ± 0.3	8	0.1 ± 0.1	8
	14 - 21	1.0 ± 0.6	8	1.1 ± 0.3	8	0.3 ± 0.2	8	0.5 ± 0.2	8	1.0 ± 0.2	8	0.9 ± 0.1	8
	21 - 28	0.5 ± 0.6	8	0.6 ± 0.4	8	0.8 ± 0.2	8	0.8 ± 0.2	8	1.2 ± 0.2	8	0.4 ± 0.1	8
	0 - 28	3.2 ± 0.3	8	3.1 ± 0.6	8	2.7 ± 0.3	8	2.7 ± 0.3	8	3.5 ± 0.2	8	1.7 ± 0.1 *	8

**Study Number:** I10482

**Test Type:** TOX

**Route:** Dosing in Feed

**Species/Strain:** Mouse/B6C3F1/N

**I04G: Mean Body Weight Gain**

**Test Compound:** N-Butylbenzenesulfonamide

**CAS Number:** 3622-84-2

**Date Report Requested:** 03/10/2023

**Time Report Requested:** 13:47:56

**Lab:** Burleson Research Technologies

---

**Females: SRBC**

---

Phase	Days	Treatment Groups (ppm)	
		50 mg/kg CPS	
		Wt Gain (g)	N
SD	0 - 7	0.8 ± 0.2	8
	7 - 14	1.0 ± 0.2	8
	14 - 21	1.4 ± 0.2	8
	21 - 28	-0.5 ± 0.3	8
	0 - 28	2.7 ± 0.4	8

Study Number: I10482

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Mouse/B6C3F1/N

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 13:47:56

Lab: Burleson Research Technologies

Females: KLH

Treatment Groups (ppm)

Phase	Days	0		313		625		1250		2500		5000	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	1.3 ± 0.2 **	8	1.2 ± 0.3	8	0.6 ± 0.3 *	8	0.5 ± 0.2 *	8	0.7 ± 0.1 *	8	0.3 ± 0.2 **	8
	7 - 14	0.8 ± 0.3	8	1.0 ± 0.4	8	1.3 ± 0.2	8	1.3 ± 0.2	8	1.1 ± 0.2	8	0.9 ± 0.1	8
	14 - 21	0.8 ± 0.2	8	-0.2 ± 0.3 *	8	0.3 ± 0.1	8	0.5 ± 0.3	8	0.4 ± 0.2	8	0.1 ± 0.1	8
	21 - 28	1.1 ± 0.4	8	1.3 ± 0.3	8	1.3 ± 0.2	8	0.7 ± 0.2	8	0.9 ± 0.1	8	0.8 ± 0.2	8
	0 - 28	4.0 ± 0.8 **	8	3.4 ± 0.3	8	3.5 ± 0.3	8	2.9 ± 0.6	8	3.1 ± 0.3	8	2.0 ± 0.3 **	8

**Study Number:** I10482

**Test Type:** TOX

**Route:** Dosing in Feed

**Species/Strain:** Mouse/B6C3F1/N

**I04G: Mean Body Weight Gain**

**Test Compound:** N-Butylbenzenesulfonamide

**CAS Number:** 3622-84-2

**Date Report Requested:** 03/10/2023

**Time Report Requested:** 13:47:56

**Lab:** Burleson Research Technologies

---

**Females: KLH**

---

Phase	Days	Treatment Groups (ppm)	
		50 mg/kg CPS	
		Wt Gain (g)	N
SD	0 - 7	0.6 ± 0.2 *	8
	7 - 14	0.9 ± 0.2	8
	14 - 21	-0.6 ± 0.1 **	8
	21 - 28	0.4 ± 0.2	8
	0 - 28	1.3 ± 0.2 *	8

**Study Number:** I10482  
**Test Type:** TOX  
**Route:** Dosing in Feed  
**Species/Strain:** Mouse/B6C3F1/N

**I04G: Mean Body Weight Gain**  
**Test Compound:** N-Butylbenzenesulfonamide  
**CAS Number:** 3622-84-2

**Date Report Requested:** 03/10/2023  
**Time Report Requested:** 13:47:56  
**Lab:** Burleson Research Technologies

**Females: Immunophenotyping**

Phase	Days	Treatment Groups (ppm)											
		0		313		625		1250		2500		5000	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	1.3 ± 0.1 **	8	0.8 ± 0.3	8	0.3 ± 0.1 **	8	0.7 ± 0.1 **	8	0.7 ± 0.2 **	8	0.0 ± 0.2 **	8
	7 - 14	1.0 ± 0.1	8	0.8 ± 0.3	8	1.3 ± 0.1	8	1.2 ± 0.2	8	1.0 ± 0.4	8	0.5 ± 0.1	8
	14 - 21	0.5 ± 0.3	8	1.3 ± 0.3	8	1.0 ± 0.4	8	0.7 ± 0.4	8	0.6 ± 0.4	8	0.3 ± 0.1	8
	21 - 28	1.3 ± 0.4	8	1.2 ± 0.3	8	1.0 ± 0.5	8	1.0 ± 0.4	8	1.3 ± 0.3	8	0.7 ± 0.1	8
	0 - 28	4.1 ± 0.4 **	8	4.2 ± 0.8	8	3.6 ± 0.4	8	3.6 ± 0.3	8	3.6 ± 0.5	8	1.6 ± 0.2 **	8

**Study Number:** I10482

**Test Type:** TOX

**Route:** Dosing in Feed

**Species/Strain:** Mouse/B6C3F1/N

**I04G: Mean Body Weight Gain**

**Test Compound:** N-Butylbenzenesulfonamide

**CAS Number:** 3622-84-2

**Date Report Requested:** 03/10/2023

**Time Report Requested:** 13:47:56

**Lab:** Burleson Research Technologies

---

**Females: Immunophenotyping**

---

Phase	Days	Treatment Groups (ppm)	
		50 mg/kg CPS	
		Wt Gain (g)	N
SD	0 - 7	0.5 ± 0.2 *	8
	7 - 14	0.8 ± 0.2	8
	14 - 21	0.6 ± 0.3	8
	21 - 28	0.5 ± 0.2	8
	0 - 28	2.4 ± 0.2 **	8

Study Number: I10482

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Mouse/B6C3F1/N

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 13:47:56

Lab: Burleson Research Technologies

Females: CTL

Treatment Groups (ppm)

Phase	Days	0		313		625		1250		2500		5000	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	0.9 ± 0.2	8	0.1 ± 0.1 *	8	0.3 ± 0.3	8	0.8 ± 0.2	8	0.4 ± 0.1	8	-0.0 ± 0.1 *	8
	7 - 14	1.1 ± 0.3 *	8	1.6 ± 0.2	8	0.9 ± 0.3	8	1.1 ± 0.1	8	0.8 ± 0.2	8	0.7 ± 0.1	8
	14 - 21	0.3 ± 0.3	8	0.4 ± 0.2	8	0.2 ± 0.1	8	0.3 ± 0.1	8	0.5 ± 0.2	8	0.4 ± 0.1	8
	21 - 28	0.0 ± 0.2 **	8	0.5 ± 0.2	8	0.3 ± 0.4	8	1.0 ± 0.3	8	-0.4 ± 0.3	8	-1.5 ± 0.4 **	8
	0 - 28	2.3 ± 0.4 **	8	2.6 ± 0.2	8	1.7 ± 0.4	8	3.2 ± 0.3	8	1.3 ± 0.4	8	-0.4 ± 0.5 **	8



**Study Number:** I10482

**Test Type:** TOX

**Route:** Dosing in Feed

**Species/Strain:** Mouse/B6C3F1/N

**I04G: Mean Body Weight Gain**

**Test Compound:** N-Butylbenzenesulfonamide

**CAS Number:** 3622-84-2

**Date Report Requested:** 03/10/2023

**Time Report Requested:** 13:47:56

**Lab:** Burleson Research Technologies

---

**Females: CTL**

---

Phase	Days	Treatment Groups (ppm)	
		50 mg/kg CPS	
		Wt Gain (g)	N
SD	0 - 7	0.6 ± 0.2	8
	7 - 14	0.8 ± 0.2	8
	14 - 21	0.3 ± 0.3	7
	21 - 28	-2.6 ± 0.3 **	7
	0 - 28	-0.7 ± 0.3 **	7

Study Number: I10482

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Mouse/B6C3F1/N

I04G: Mean Body Weight Gain

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 03/10/2023

Time Report Requested: 13:47:56

Lab: Burleson Research Technologies

Females: Immunopath

Treatment Groups (ppm)

Phase	Days	0		313		625		1250		2500		5000	
		Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N	Wt Gain (g)	N
SD	0 - 7	0.1 ± 0.2 **	8	-0.1 ± 0.2	8	0.4 ± 0.1	8	-0.0 ± 0.2	8	-0.4 ± 0.1	8	-0.7 ± 0.2 **	8
	7 - 14	0.9 ± 0.3	8	0.7 ± 0.2	8	0.7 ± 0.2	8	1.1 ± 0.1	8	1.2 ± 0.2	8	0.3 ± 0.1	8
	14 - 21	1.4 ± 0.3	8	0.7 ± 0.1	8	0.5 ± 0.2 *	8	1.7 ± 0.3	8	1.0 ± 0.3	8	0.5 ± 0.1 *	8
	21 - 28	0.0 ± 0.3	8	0.5 ± 0.2	8	1.0 ± 0.2 *	8	0.4 ± 0.3	8	0.7 ± 0.4	8	0.7 ± 0.2	8
	0 - 28	2.4 ± 0.4	8	1.8 ± 0.3	8	2.5 ± 0.4	8	3.2 ± 0.2	8	2.6 ± 0.2	8	0.9 ± 0.3 **	8

**Study Number:** I10482

**Test Type:** TOX

**Route:** Dosing in Feed

**Species/Strain:** Mouse/B6C3F1/N

**I04G: Mean Body Weight Gain**

**Test Compound:** N-Butylbenzenesulfonamide

**CAS Number:** 3622-84-2

**Date Report Requested:** 03/10/2023

**Time Report Requested:** 13:47:56

**Lab:** Burleson Research Technologies

---

**Females: Immunopath**

---

Phase	Days	Treatment Groups (ppm)	
		50 mg/kg CPS	
		Wt Gain (g)	N
SD	0 - 7	-0.0 ± 0.2	8
	7 - 14	0.8 ± 0.1	8
	14 - 21	1.0 ± 0.2	8
	21 - 28	0.4 ± 0.2	8
	0 - 28	2.1 ± 0.4	8

**Study Number:** I10482

**Test Type:** TOX

**Route:** Dosing in Feed

**Species/Strain:** Mouse/B6C3F1/N

**I04G: Mean Body Weight Gain**

**Test Compound:** N-Butylbenzenesulfonamide

**CAS Number:** 3622-84-2

**Date Report Requested:** 03/10/2023

**Time Report Requested:** 13:47:56

**Lab:** Burleson Research Technologies

#### LEGEND

---

Data are displayed as mean  $\pm$  SEM

SD – Study Day

Statistical analysis of weight data performed by Jonckheere (trend) and Williams or Dunnett (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the t-Test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

\* Statistically significant at  $P \leq 0.05$

\*\* Statistically significant at  $P \leq 0.01$

CPS = Cyclophosphamide

**\*\* END OF REPORT \*\***